News
Sarepta Shares Rise After Company Says It Will Resume Elevidys Shipments
Shares of Sarepta surged Tuesday, a day after the FDA said the company could lift a voluntary pause on shipments of its Elevidys drug, which had been linked to three patient deaths this year. The stock was up 26% at $17.45 Tuesday but is still down 86% so far this year.
The drug, which was designed to treat Duchenne muscular dystrophy, has been linked to the deaths of two teenage boys.
Sarepta Therapeutics said the Food and Drug Administration informed the company it can lift a voluntary pause on shipments of Elevidys for ambulatory patients with Duchenne. The company said Monday ...
STAT News Video - Video on MSN2d
The story of Sarepta's Duchenne gene therapyThe last couple of weeks has been particularly distressing for Duchenne muscular dystrophy patients and their families. The ...
Stocktwits on MSN3d
FDA Official Who Halted Sarepta’s Gene Therapy Resigns Amid Backlash Over Access To Duchenne TreatmentVinay Prasad has stepped down as head of the FDA’s biologics division just two months into the job, following growing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback